Dissecting "PI3Kness": The Complexity of Personalized Therapy for Ovarian Cancer

被引：27

作者：

Bast, Robert C., Jr. ^{[1
]}

Mills, Gordon B.

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA

来源：

CANCER DISCOVERY | 2012年 / 2卷 / 01期

关键词：

ONCOGENE; 3-KINASE; PIK3CA;

D O I：

10.1158/2159-8290.CD-11-0323

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Epithelial ovarian cancers exhibit marked heterogeneity and can be divided into low-grade type I and more prevalent high-grade type II lesions that differ in stage at diagnosis, rate of growth, and susceptibility to platinum-based chemotherapy. Activation of the phosphatidylinositol 3' inase (PI3K) pathway occurs in a significant fraction of both types of ovarian cancer, driven predominantly by mutations in type I and amplification in type II. Available cell lines do not often reflect the genotype of type II ovarian cancers, but studies with cell lines driven by mutation suggest that blocking activated AKT is necessary, but not sufficient to inhibit cancer cell growth. Inhibition of multiple signaling pathways will likely be required to achieve effective personalized therapy for patients whose cancers exhibit "PI3Kness." Cancer Discovery; 2(1); 16-8. (C) 2012 AACR.

引用

页码：16 / 18

页数：3

共 13 条

[1] The biology of ovarian cancer: new opportunities for translation [J].

Bast, Robert C., Jr. ;

Hennessy, Bryan ;

Mills, Gordon B. .

NATURE REVIEWS CANCER, 2009, 9 (06) :415-428

[2] Integrated genomic analyses of ovarian carcinoma [J].

Bell, D. ;

Berchuck, A. ;

Birrer, M. ;

Chien, J. ;

Cramer, D. W. ;

Dao, F. ;

Dhir, R. ;

DiSaia, P. ;

Gabra, H. ;

Glenn, P. ;

Godwin, A. K. ;

Gross, J. ;

Hartmann, L. ;

Huang, M. ;

Huntsman, D. G. ;

Iacocca, M. ;

Imielinski, M. ;

Kalloger, S. ;

Karlan, B. Y. ;

Levine, D. A. ;

Mills, G. B. ;

Morrison, C. ;

Mutch, D. ;

Olvera, N. ;

Orsulic, S. ;

Park, K. ;

Petrelli, N. ;

Rabeno, B. ;

Rader, J. S. ;

Sikic, B. I. ;

Smith-McCune, K. ;

Sood, A. K. ;

Bowtell, D. ;

Penny, R. ;

Testa, J. R. ;

Chang, K. ;

Dinh, H. H. ;

Drummond, J. A. ;

Fowler, G. ;

Gunaratne, P. ;

Hawes, A. C. ;

Kovar, C. L. ;

Lewis, L. R. ;

Morgan, M. B. ;

Newsham, I. F. ;

Santibanez, J. ;

Reid, J. G. ;

Trevino, L. R. ;

Wu, Y. -Q. ;

Wang, M. .

NATURE, 2011, 474 (7353) :609-615

[3] Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup [J].

Bookman, Michael A. ;

Brady, Mark F. ;

McGuire, William P. ;

Harper, Peter G. ;

Alberts, David S. ;

Friedlander, Michael ;

Colombo, Nicoletta ;

Fowler, Jeffrey M. ;

Argenta, Peter A. ;

De Geest, Koen ;

Mutch, David G. ;

Burger, Robert A. ;

Swart, Ann Marie ;

Trimble, Edward L. ;

Accario-Winslow, Chrisann ;

Roth, Lawrence M. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) :1419-1425

[4] AKT2, A PUTATIVE ONCOGENE ENCODING A MEMBER OF A SUBFAMILY OF PROTEIN-SERINE THREONINE KINASES, IS AMPLIFIED IN HUMAN OVARIAN CARCINOMAS [J].

CHENG, JQ ;

GODWIN, AK ;

BELLACOSA, A ;

TAGUCHI, T ;

FRANKE, TF ;

HAMILTON, TC ;

TSICHLIS, PN ;

TESTA, JR .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (19) :9267-9271

[5] Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers [J].

Engelman, Jeffrey A. ;

Chen, Liang ;

Tan, Xiaohong ;

Crosby, Katherine ;

Guimaraes, Alexander R. ;

Upadhyay, Rabi ;

Maira, Michel ;

McNamara, Kate ;

Perera, Samanthi A. ;

Song, Youngchul ;

Chirieac, Lucian R. ;

Kaur, Ramneet ;

Lightbown, Angela ;

Simendinger, Jessica ;

Li, Timothy ;

Padera, Robert F. ;

Garcia-Echeverria, Carlos ;

Weissleder, Ralph ;

Mahmood, Umar ;

Cantley, Lewis C. ;

Wong, Kwok-Kin .

NATURE MEDICINE, 2008, 14 (12) :1351-1356

[6] Genomic Complexity and AKT Dependence in Serous Ovarian Cancer [J].

Hanrahan, Aphrothiti J. ;

Schultz, Nikolaus ;

Westfal, Maggie L. ;

Sakr, Rita A. ;

Giri, Dilip D. ;

Scarperi, Stefano ;

Janikariman, Manickam ;

Olvera, Narciso ;

Stevens, Ellen V. ;

She, Qing-Bai ;

Aghajanian, Carol ;

King, Tari A. ;

de Stanchina, Elisa ;

Spriggs, David R. ;

Heguy, Adriana ;

Taylor, Barry S. ;

Sander, Chris ;

Rosen, Neal ;

Levine, Douglas A. ;

Solit, David B. .

CANCER DISCOVERY, 2012, 2 (01) :56-67

[7] Akt signalling in health and disease [J].

Hers, Ingeborg ;

Vincent, Emma E. ;

Tavare, Jeremy M. .

CELLULAR SIGNALLING, 2011, 23 (10) :1515-1527

[8]

Hu LM, 2000, CLIN CANCER RES, V6, P880

[9]

Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI [10.3322/caac.20006, 10.3322/caac.21387]

[10] Oncogenic transformation induced by membrane-targeted Akt2 and Akt3 [J].

Mende, I ;

Malstrom, S ;

Tsichlis, PN ;

Vogt, PK ;

Aoki, M .

ONCOGENE, 2001, 20 (32) :4419-4423

← 1 2 →